TTCI Supports Speakers at APHIA 2025 [Bangkok, Thailand] – 21 Nov 2024The Thailand Hub of Talents in Cancer Immunotherapy (TTCI) is proud to support speakers at the Asia-Pacific Histocompatibility...
Researchers from Chulalongkorn University have developed a new weapon against glioblastoma, a notoriously difficult-to-treat brain cancer, in the form of a brand-new antibody. This antibody is a key component...
CD99 is highly expressed in T cell acute lymphoblastic leukemia (T-ALL), a type of cancer. One promising treatment involves a mouse monoclonal antibody against CD99 called mAb MT99/3, which...
A new humanized antibody, derived from a mouse antibody, has been engineered to target CD99, a protein overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). The...
Image by ChulalongkornHospital New options for cancer treatment with immunotherapy. Oct 28, 2024 🩺✨ Understanding NK Cells: A Potential Cancer Treatment ✨🩺 Summary from Dr. Kamit Supapipat at Cellular...
Innovations and Networks in Immunotherapy: Bridging Academia and Clinical Applications! Date: December 18, 2024Time: 8:30 AM – 5:00 PMVenue: Chiang Mai University Don’t miss the “Innovations and Networks in...
Researchers have developed a new approach to T cell therapy that is more effective in killing breast cancer cells. This new approach uses bispecific T cell engagers (BITEs) to...
A follow-up study on 50 adults investigated the impact of PM2.5 exposure on ocular health. Samples were collected before and after the high PM2.5 season, utilizing data from the...
Don’t believe in treating cancer with NK cells, doctors clarify the true story. No other country in the world has done it. October 30, 2024 The Hematological Society of...
